Generate Biomedicines, Inc.
Key Metrics
Market Snapshot
About
Generate Biomedicines, Inc. (GENB) is a biotechnology company headquartered in Somerville, Massachusetts. It is best known for pioneering a field termed generative biology, which applies machine learning and computational methods to discover and design new protein-based therapeutic drugs.
The company's core offering is its proprietary Generate Platform. This integrated system is designed to be agnostic to specific diseases or protein types, combining advanced computational algorithms with high-throughput laboratory hardware. The platform's goal is to program novel protein therapeutics that address complex biological challenges which traditional drug discovery methods may struggle to solve. Generate Biomedicines aims to accelerate and expand the pipeline of potential treatments through this technology-driven approach.
The company's pipeline includes several investigational therapies developed using its platform. These candidates span different therapeutic modalities and include GB-0895, a long-acting monoclonal antibody being studied for severe asthma, GB-4362, an antibody designed to neutralize a specific drug payload, and GB-5267, a cell therapy targeting a particular antigen. Founded in 2018 and originally named Generate Biologics, Inc., the company rebranded to Generate Biomedicines in early 2020 to reflect its broader focus on generative biology across biomedicines.